BackgroundHuman epidermal growth factor receptor 2(HER-2) is the most prominent therapeutic target for gastric (G)/gastroesophageal junction (GEJ) cancer. Guidelines recommend its use for treating G/GEJ cancers. However. targeted therapy did not significantly improve survival outcomes compared to those with neoadjuvant therapy. https://www.rivervalleydanceac.com/product-category/pants/
Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
Internet 44 minutes ago tesdqsr1igvp6
Web Directory Categories
Web Directory Search
New Site Listings